Stefano Fanti - Böcker

Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.

In this issue of PET Clinics, guest editors Drs. Cristina Nanni, Paolo Castellucci, Stefano Fanti, and Neeta Pandit-Taskar bring their considerable expertise to the topic of Novel PET Imaging Techniques in the Management of Hematological Malignancies. Top experts in the field discuss the latest radiotracers for lymphoma and myeloma, novel quantitative imaging techniques, radioligand therapies, total body PET imaging; and more.

This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/orevaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists.

This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact.

This atlas is a concise but comprehensive guide to the diverse patterns of response to immunotherapy as observed on Positron Emission Tomography/Computed Tomography (PET/CT) and other conventional imaging modalities, including CT and Magnetic Resonance Imaging (MRI). The purpose for this publication is to fill the gap between the growing clinical relevance and utilization of immunotherapy in medical oncology, mainly based on checkpoint inhibitors, and the need for experienced imagers with reliable tools assessing response to treatment. A series of disease-oriented chapters will present the imaging findings during immunotherapy in the major oncological settings, with helpful comparison of functional (PET/CT) and morphological (CT/MRI) patterns of response in individual cases. To complete the atlas, a dedicated chapter will focus on major pitfalls and immune-related adverse events (irAEs) affecting image interpretation during the course of immunotherapy. The concluding chapter will lastly examine the available data and potential developments of immuno-PET, which is considered as the novel frontier of research in this oncological scenario. The atlas will be of high value for radiologists and nuclear medicine specialists at all levels of experience.

This atlas is a concise but comprehensive guide to the diverse patterns of response to immunotherapy as observed on Positron Emission Tomography/Computed Tomography (PET/CT) and other conventional imaging modalities, including CT and Magnetic Resonance Imaging (MRI).

This is the first book to explore the epistemology and ethics of advanced imaging tests, in order to improve the critical understanding of the nature of knowledge they provide and the practical consequences of their utilization in healthcare.

This atlas is a superb guide to the use of PET-CT for the evaluation of treatment response in oncology patients based on its ability to assess tumor metabolic status.

This atlas is intended to enable nuclear medicine practitioners who routinely read PET/CT scans to recognize the most common CT abnormalities. Reading PET/CT scans can sometimes be challenging. It is not infrequent, in fact, to encounter abnormal findings in CT images (not related to the neoplastic disease under evaluation) that are functionally silent and therefore difficult to interpret for nuclear medicine practitioners. Frequently, these findings are clinically relevant and should be reported, interpreted and compared to previous scans. This may also have an impact on patient management, since expensive tests like PET/CT are expected to provide the highest level of diagnostic information. Generally, CT images associated with a PET scan are acquired in a low-dose modality, and therefore prove to be sub-optimal for CT image interpretation. Sometimes a comparison with a full-resolution and contrast-enhanced CT atlas may be difficult. Low-dose CT slices are thicker than diagnostic CT and offer less anatomical detail, which can affect accuracy in terms of recognizing both anatomical structures and pathological findings.Today it is becoming increasingly common to acquire a standard PET/CT by combining the administration of contrast media and a diagnostic CT; here, too, basic CT reporting skills are needed in clinical practice. This atlas features a chapter on “normal anatomy” (with and without contrast media) that is based on low-dose and full-dose CT images from PET/CT standard acquisition, and which identifies all the relevant anatomical structures. Other chapters (focusing on the thorax, abdomen, pelvis, and musculoskeletal system) present cases with common and uncommon anatomical abnormalities. The addition of new cases with ceCT in this revised second edition rounds out the coverage of PET/CT reporting. Given its scope, the book will be of interest to nuclear medicine physicians, radiologists, and oncologists alike.

Low-dose CT slices are thicker than diagnostic CT and offer less anatomical detail, which can affect accuracy in terms of recognizing both anatomical structures and pathological findings.Today it is becoming increasingly common to acquire a standard PET/CT by combining the administration of contrast media and a diagnostic CT;

This book reviews the important new field of PET/CT-guided biopsy, which is of potential value in optimizing the diagnostic yield of biopsies. The role of this technology is examined in a range of malignancies, including lymphoma, pancreatic, breast cancer and CNS malignancies. True positive and false positive cases are presented and discussed, and many aspects of PET and pathology are addressed. The book describes many case presentations illustrated with mostly 18F-FDG PET/CT images, but also other PET radiopharmaceuticals such as 18F-FLT. The three editors are expert nuclear medicine physicians from Europe and North and South America, and the range of experiences gained in using PET/CT across the globe is reflected in the book.

This pocket book provides up-to-date descriptions of the most relevant features of neuroendocrine tumors (NETs) and the imaging modalities currently available to assist specialists (clinicians, pathologists, radiologists, nuclear medicine physicians) in selecting optimal patient management based on interdisciplinary collaboration.

This book reviews the important new field of PET/CT-guided biopsy, which is of potential value in optimizing the diagnostic yield of biopsies. The three editors are expert nuclear medicine physicians from Europe and North and South America, and the range of experiences gained in using PET/CT across the globe is reflected in the book.

Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which other radiopharmaceuticals offer advantages. This atlas, including about 500 high-quality images, is a user-friendly guide to PET-CT imaging beyond FDG.

The field of nuclear medicine has evolved rapidly in recent years, and one very important aspect of this progress has been the introduction of hybrid imaging systems. PET-CT has already gained widespread acceptance in many clinical settings, especially within oncology, and now SPECT-CT promises to emulate its success.

PET-CT is increasingly being employed in the diagnosis of both oncological and non-oncological patients, yet nuclear medicine physicians may have only limited practical experience of rare diseases and may experience difficulty in recognizing and interpreting rare findings. This unique atlas documents a large number of clinical cases that will help practitioners to identify findings and diseases that, though rare, are sufficiently frequent to be encountered in routine practice. Two types of cases are presented: patients evaluated for rare diseases and patients evaluated for standard diseases in whom atypical PET findings were detected. Each reported case includes a brief description of the clinical history, representative color PET-CT images obtained using FDG or other tracers, and a short explanation of the disease and findings. This atlas will enable practitioners to make conclusive reports of PET-CT scans that would otherwise have been inconclusive.